Healthcare Review: Ariad Pharmaceuticals, Oramed Pharmaceuticals, BioCryst Pharmaceuticals, Jazz Pharmaceuticals, Amarin Print E-mail
By Staff and Wire Reports   
Friday, 20 December 2013 19:49
U.S. stocks jumped on Friday after the U.S. government said the economy grew at its briskest pace in nearly two years, while the euro held steady, paring earlier losses after Standard & Poor's stripped the European Union of its triple-A credit rating. Gold rebounded from a six-month low, but was on track for its biggest annual loss in more than three decades, as investors dumped the precious metal after the U.S. Federal Reserve decided to reduce its bond purchases. The Fed's decision Wednesday to begin tapering its $85-billion monthly bond purchases in January has hurt medium-dated U.S. government debt but supported longer-dated U.S. government debt.

Ariad Pharmaceuticals ($ARIA) says the FDA has approved a revised USPI and a REMS for Iclusig. The move "allows immediate resumption of its marketing and commercial distribution." The drug, which was suspended in October, is now indicated for "T315I-positive chronic myeloid leukemia or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia and chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated."The boxed warning is revised and now features an alert regarding "the risk of vascular occlusive events." There's also "a new warning for heart failure."

BioCryst Pharmaceuticals ($BCRX) jumps 5.7% after the company has submitted a NDA for IV peramivir in acute uncomplicated influenza in adults. BCRX got a small business waiver for the application fee.

Oramed Pharmaceuticals ($ORMP) rises 34% after the company says "patient responses positively correlated with administered doses, as did the duration of the effect," in a study testing the pharmacokinetic dose response of ORMD-0801 in type 1 diabetes. ORMP will "continue to move forward with this indication" along with studies in type 2 diabetes.

Shares of Jazz Pharmaceuticals ($JAZZ) are 7% higher on the heels of the company's Gentium (GENT) acquisition. The deal gives the company Defitelio — the sVOD treatment that also has an Orphan designation in the EU for GvHD — which JAZZ says "is highly complementary to [the company's] experience in and focus on orphan diseases in the area of hematology/oncology."JAZZ expects the deal to be immediately accretive.

The FDA has indefinitely delayed a ruling on Amarin's ($AMRN) request to expand the use of of the company's Vascepa drug, which lowers triglyceride fat in blood.  Under the new "ANCHOR" indication, the therapy would be used to treat people who take statins to cut cholesterol and have a high risk of coronary heart disease. The FDA was due to issue its verdict today, but the agency put off the ruling as it's still considering Amarin's request to re-instate the ANCHOR Special Protocol Assessment (SPA) agreement. Under the SPA, the FDA had said that the design of an uncompleted Phase III trial was acceptable to support a marketing application to widen Vascepa's use case. However, the agency rescinded that SPA in October and initially denied Amarin's appeal over the matter.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter